IBDEI13Z ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18511,1,4,0)
 ;;=4^E06.0
 ;;^UTILITY(U,$J,358.3,18511,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,18512,0)
 ;;=E06.1^^94^908^54
 ;;^UTILITY(U,$J,358.3,18512,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18512,1,3,0)
 ;;=3^Thyroiditis,Subacute
 ;;^UTILITY(U,$J,358.3,18512,1,4,0)
 ;;=4^E06.1
 ;;^UTILITY(U,$J,358.3,18512,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,18513,0)
 ;;=C73.^^94^908^37
 ;;^UTILITY(U,$J,358.3,18513,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18513,1,3,0)
 ;;=3^Malig Neop of Thyroid Gland
 ;;^UTILITY(U,$J,358.3,18513,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,18513,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,18514,0)
 ;;=E10.21^^94^908^8
 ;;^UTILITY(U,$J,358.3,18514,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18514,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,18514,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,18514,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,18515,0)
 ;;=E10.9^^94^908^12
 ;;^UTILITY(U,$J,358.3,18515,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18515,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,18515,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,18515,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,18516,0)
 ;;=E11.21^^94^908^17
 ;;^UTILITY(U,$J,358.3,18516,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18516,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,18516,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,18516,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,18517,0)
 ;;=E11.39^^94^908^18
 ;;^UTILITY(U,$J,358.3,18517,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18517,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,18517,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,18517,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,18518,0)
 ;;=E11.43^^94^908^15
 ;;^UTILITY(U,$J,358.3,18518,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18518,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,18518,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,18518,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,18519,0)
 ;;=E11.59^^94^908^13
 ;;^UTILITY(U,$J,358.3,18519,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18519,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,18519,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,18519,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,18520,0)
 ;;=E11.618^^94^908^14
 ;;^UTILITY(U,$J,358.3,18520,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18520,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,18520,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,18520,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,18521,0)
 ;;=E11.621^^94^908^16
 ;;^UTILITY(U,$J,358.3,18521,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18521,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,18521,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,18521,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,18522,0)
 ;;=E11.622^^94^908^20
 ;;^UTILITY(U,$J,358.3,18522,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18522,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,18522,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,18522,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,18523,0)
 ;;=E11.65^^94^908^19
 ;;^UTILITY(U,$J,358.3,18523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18523,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,18523,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,18523,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,18524,0)
 ;;=E11.9^^94^908^21
 ;;^UTILITY(U,$J,358.3,18524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18524,1,3,0)
 ;;=3^DM Type 2 w/o Complications
